Casomorphin

What is Casomorphin?

Casomorphins are a family of opioid-active peptides released by partial proteolytic digestion of bovine beta-casein, the principal protein of cow milk. The seven-residue beta-casomorphin-7 (BCM-7, sequence Tyr-Pro-Phe-Pro-Gly-Pro-Ile, derived from positions 60-66 of bovine beta-casein A1) is the most studied member of the family. Beta-casomorphin-5 (BCM-5, the N-terminal pentapeptide) is also pharmacologically active. Both retain the canonical 'message' tetrapeptide Tyr-Pro-Phe-Pro that defines mammalian mu-opioid receptor binding pharmacophores, structurally analogous to the morphiceptins and to endomorphin-1 and endomorphin-2. Casomorphins were discovered in 1979 by Victor Brantl, Hansjörg Teschemacher, Agnes Henschen, and colleagues at the Max-Planck-Institut für Psychiatrie in Munich while searching for food-derived peptides with bioactivity at central nervous system receptors. The 1979 Hoppe-Seyler's Zeitschrift papers (Brantl: isolation; Henschen: structure) introduced the field of food-derived opioid peptides, now collectively termed 'exorphins.' Beta-casomorphin-7 is the centerpiece of the long-running A1-versus-A2 milk debate: bovine beta-casein has two principal genetic variants (A1 and A2) differing only at residue 67 — A1 has histidine at position 67 (allowing efficient gastrointestinal release of BCM-7), while A2 has proline at position 67 (which dramatically slows the proteolytic release). A2-only milk (from cows genetically selected to produce only A2 beta-casein) has been promoted as a 'gentler' alternative to standard mixed-A1/A2 milk based on claims that BCM-7 contributes to gastrointestinal symptoms in some milk-drinkers, with most rigorous trials reporting modest GI-symptom differences and the regulatory bodies (EFSA in particular) concluding that the broader health-claim evidence base remains inconclusive. Casomorphins are not a self-administered peptide therapeutic; they are a food-chemistry topic with implications for milk processing, infant nutrition, and dairy genetics.

What Casomorphin Is Investigated For

Casomorphin is a food-chemistry and consumer-debate topic, not a peptide consumers self-administer. Three lines of relevance organize the discussion. First, the in vitro pharmacology: BCM-7 and BCM-5 are bona fide mu-opioid receptor agonists in receptor-binding assays and isolated-tissue preparations, with affinity in the low-micromolar range — substantially weaker than morphine but sufficient to be measurable. The relevant pharmacology question is whether dietary BCM-7 reaches the central nervous system or systemic circulation in concentrations sufficient to produce opioid effects, and the answer in adults with intact gastrointestinal barriers and normal dipeptidyl peptidase IV activity is largely no (BCM-7 is rapidly degraded in the small intestine and barely crosses the gut epithelium). Second, the A1/A2 milk debate: a single amino acid difference at position 67 of bovine beta-casein (histidine in A1, proline in A2) controls whether BCM-7 is efficiently released by gastrointestinal proteolysis. A2-only milk has been heavily marketed as gentler on the gut, with reasonably consistent (if modest) trial evidence for reduced gastrointestinal symptoms in some milk-sensitive individuals — but EFSA's 2009 scientific opinion concluded that the broader health-claim literature (autism, schizophrenia, type 1 diabetes, cardiovascular disease) does not support specific causal claims for BCM-7. Third, infant and pediatric exposure: human milk has its own beta-casein with somewhat different proteolytic kinetics, and infant formulas based on cow milk contain measurable BCM-7 — a topic that has driven both research interest and dietary-policy debate without producing settled conclusions. The honest framing is that casomorphins are real bioactive peptides, the A1/A2 difference is a real biochemical phenomenon, and there is a defensible case for A2 milk in milk-sensitive individuals — but the broader health claims that have been attached to BCM-7 over four decades have not held up to rigorous scrutiny.

History & Discovery

Beta-casomorphins were discovered in 1979 by Victor Brantl, Hansjörg Teschemacher, Agnes Henschen, and Friedrich Lottspeich at the Max-Planck-Institut für Psychiatrie in Munich. The team had been investigating whether food proteins might be sources of bioactive peptides with central nervous system activity, and screened proteolytic digests of bovine casein for opioid-receptor binding activity using the guinea pig ileum and mouse vas deferens isolated-tissue preparations. They identified opioid-active peptides in casein peptone and characterized them as a series of N-terminal beta-casein fragments — most prominently beta-casomorphin-7 (residues 60-66 of bovine beta-casein) and beta-casomorphin-5 (the N-terminal pentapeptide). The two companion 1979 Hoppe-Seyler's Zeitschrift für physiologische Chemie papers (Brantl: isolation; Henschen: structure) introduced the concept of food-derived opioid peptides — peptides not produced by the human body but released by digestion of dietary proteins. Brantl coined the term 'exorphin' (exogenous endorphin) to describe this class. Subsequent work in the 1980s identified additional exorphins from gluten (gluteomorphins), hemoglobin (hemorphins), and other dietary proteins, establishing food-derived opioid pharmacology as a small but durable subfield of peptide research. The A1-versus-A2 beta-casein story developed in parallel through the 1980s and 1990s. Bovine beta-casein had been recognized as having multiple genetic variants since the 1960s, with A1 and A2 the most clinically relevant in modern dairy herds. The biochemical observation that A1 beta-casein (with histidine at position 67) releases BCM-7 readily during proteolysis, while A2 beta-casein (with proline at position 67) does not, was characterized through the 1980s and 1990s. The commercial implications — that herds bred to produce only A2 beta-casein would yield milk with minimal BCM-7 release — drove genetic-testing and selective-breeding programs. The A2 Corporation (later A2 Milk Company) in New Zealand commercialized A2-only milk in the early 2000s, and the A1-versus-A2 milk debate became a fixture of consumer dairy marketing in Australia, New Zealand, the U.K., the U.S., and other markets through the 2010s and 2020s. The broader health-claim literature attached to A1 beta-casein and BCM-7 expanded substantially through the 2000s. Hypotheses proposed causal links to autism spectrum disorder (the 'opioid excess' theory of autism, which had originated in the 1970s and gained traction in alternative-medicine circles through the 1990s and 2000s), schizophrenia (extending the older exorphin-and-psychosis hypothesis), type 1 diabetes (through proposed molecular mimicry between BCM-7 and beta-cell antigens, an idea advanced by Bob Elliott and the New Zealand research community), cardiovascular disease (through proposed inflammatory and metabolic mechanisms), and sudden infant death syndrome. None of these hypotheses gained traction in the mainstream peer-reviewed literature. The European Food Safety Authority (EFSA) commissioned a comprehensive review of the BCM-7 health-effects literature published as a 2009 scientific opinion. The conclusion was that a causal relationship between BCM-7 (or A1 beta-casein) and non-communicable disease was not established. EFSA noted that BCM-7 is a real bioactive peptide with measurable mu-opioid receptor pharmacology, that A1-versus-A2 differences in BCM-7 release are real, but that the proposed systemic-disease links did not survive rigorous methodological review. Subsequent comprehensive reviews (Kamiński 2007 J Appl Genet; Cieślińska 2022 Int J Mol Sci, the standard modern reference) have largely sustained this conclusion while leaving room for legitimate research on local gastrointestinal effects in milk-sensitive individuals. As of 2026, A2 milk remains a commercially significant product category with reasonable evidence for modest GI-symptom benefits in some individuals, and the broader BCM-7 health claims remain unsupported.

How It Works

Casomorphin is a small piece of milk protein that has weak opioid (morphine-like) activity. When you drink cow milk, your stomach and intestines break down the casein protein, and one of the fragments — beta-casomorphin-7, or BCM-7 — happens to bind the same opioid receptors that morphine does, just much more weakly. This is interesting biology, and it's one reason 'A2 milk' (from cows that don't produce the kind of beta-casein that releases BCM-7 efficiently) has been marketed as gentler on the gut. The reality is more boring than the marketing: most BCM-7 gets broken down in your gut before it can do anything systemic, the in-gut effects on motility are mild, and the bigger health claims (autism, schizophrenia, SIDS) that have been attached to BCM-7 over the decades have not held up under scrutiny.

Beta-casomorphins are opioid-active peptide fragments released by gastrointestinal proteolysis of bovine beta-casein, the principal protein component of cow milk. The bovine beta-casein gene (CSN2) on chromosome 6 encodes a 224-residue protein that exists in multiple genetic variants, of which A1 and A2 are the most clinically relevant in modern dairy herds. The A1 and A2 variants differ at amino acid position 67 — A1 has histidine, A2 has proline — and this single difference dictates whether the relevant proteolytic cleavage that releases beta-casomorphin-7 (BCM-7, residues 60-66) occurs efficiently. With histidine at position 67 (A1), gastrointestinal proteases (trypsin, chymotrypsin, elastase) cleave the peptide bond between residues 66 and 67 to release BCM-7 readily. With proline at position 67 (A2), this cleavage is dramatically slowed because proline introduces a peptide-bond conformation that resists protease access — so A2 beta-casein releases negligible BCM-7 during normal gastrointestinal digestion. BCM-7 (sequence Tyr-Pro-Phe-Pro-Gly-Pro-Ile) and its N-terminal pentapeptide BCM-5 (Tyr-Pro-Phe-Pro-Gly) retain the 'message' tetrapeptide Tyr-Pro-Phe-Pro that defines mammalian mu-opioid receptor binding pharmacophores. This is the same N-terminal motif present in the morphiceptins (the original mu-opioid-selective tetrapeptide pharmacology series) and structurally related to the endogenous endomorphin-1 and endomorphin-2 (Tyr-Pro-Trp-Phe-NH2 and Tyr-Pro-Phe-Phe-NH2 respectively). BCM-7 binds mu-opioid receptors in receptor-binding assays with low-micromolar affinity — substantially weaker than morphine, endorphin, or endomorphin, but pharmacologically real. It produces measurable opioid effects in isolated-tissue preparations including the guinea pig ileum and mouse vas deferens at the same low-micromolar concentrations. Whether dietary BCM-7 reaches systemic circulation and the central nervous system in concentrations sufficient to produce opioid effects is a separate question. In adults with intact gastrointestinal barriers and normal dipeptidyl peptidase IV (DPP-4, CD26) activity, BCM-7 is rapidly degraded by intestinal aminopeptidases — DPP-4 in particular cleaves the N-terminal Tyr-Pro dipeptide, abolishing opioid activity. Very little intact BCM-7 crosses the intestinal epithelium, and systemic plasma concentrations are minimal even after substantial dairy intake. Locally-acting opioid effects on intestinal mu-opioid receptors (which slow gastrointestinal motility, contribute to constipation, and can cause bloating) are more plausible than centrally-mediated effects, and may underlie the modest A1-versus-A2 gastrointestinal-symptom differences observed in some clinical trials. Subpopulations with reduced gut-barrier integrity, reduced DPP-4 activity (which has been described in association with some disease states), or pediatric immaturity of barrier function have been proposed to be more susceptible to systemic BCM-7 exposure — but the evidence for clinically meaningful effects in any specific subpopulation remains modest. The broader health-claim literature attached to BCM-7 — proposing causal links to autism spectrum disorder (through a 'leaky gut' opioid hypothesis), schizophrenia (through exorphins as factors in psychotic-spectrum illness), type 1 diabetes (through molecular mimicry between BCM-7 and beta-cell antigens), cardiovascular disease (through inflammatory and metabolic mechanisms), and sudden infant death syndrome — was reviewed by the European Food Safety Authority (EFSA) in 2009. EFSA's scientific opinion concluded that a causal relationship between BCM-7 (or A1 beta-casein) and non-communicable disease was not established. Subsequent comprehensive reviews (Kamiński 2007 J Appl Genet; Cieślińska 2022 Int J Mol Sci) have largely sustained this conclusion, with continuing research focused on the more defensible local gastrointestinal effects rather than the broader systemic-disease claims.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Casomorphin:

• 01Whether the modest A1-versus-A2 milk gastrointestinal-symptom differences observed in some clinical trials replicate at population scale and whether specific subpopulations (irritable bowel syndrome, functional dyspepsia, dairy-sensitive individuals) show reproducibly larger benefits.
• 02Whether dietary BCM-7 exposure has clinically significant effects in subpopulations with reduced gut-barrier integrity (post-surgical, IBD, celiac disease) or low DPP-4 activity (some disease states and pharmacologic conditions).
• 03The long-term implications of cumulative dietary BCM-7 exposure across the lifespan, particularly in early life through formula feeding and dairy introduction.
• 04Whether the broader food-derived opioid peptide field (gluteomorphins, hemorphins, casomorphins, soymorphins, others) collectively contributes to dietary effects on appetite, mood, gastrointestinal symptoms, or other outcomes — currently studied in fragments rather than as an integrated dietary opioid burden.
• 05Whether DPP-4 inhibitors used for type 2 diabetes meaningfully alter dietary BCM-7 lifetime in the gut and downstream effects.
• 06The role of microbiome-mediated proteolysis in modulating BCM-7 release from dietary beta-casein, beyond host enzymatic digestion.
• 07Whether genetic variation in human DPP-4, opioid receptors, or gut barrier function identifies subpopulations more susceptible to BCM-7 effects.

Forms & Administration

Casomorphin is not formulated or approved as a therapeutic. Consumer exposure is exclusively dietary through dairy products containing bovine beta-casein. A1-containing milk, butter, cheese, and other dairy products release BCM-7 during gastrointestinal proteolysis; A2-only milk releases negligible BCM-7. Synthetic BCM-7 is sold by peptide reference-standard vendors for laboratory research use (in vitro receptor binding, isolated-tissue pharmacology, animal studies of intestinal absorption and effects), but has no clinical formulation or approved use. Compounded BCM-7 in consumer peptide marketplaces has no validated clinical use and no plausible administration regimen.

Common Questions

Who Casomorphin Is NOT For

Drug & Supplement Interactions

There are no validated clinical drug-interaction profiles for casomorphin because it is not administered as a therapeutic. Dietary BCM-7 exposure through dairy products is rapidly degraded by intestinal DPP-4 and aminopeptidases, with minimal systemic absorption — making clinically meaningful systemic drug interactions implausible. Local intestinal mu-opioid receptor effects of BCM-7 could theoretically interact with: opioid medications (additive constipation through intestinal motility slowing); peripheral opioid receptor antagonists used for opioid-induced constipation (methylnaltrexone, naloxegol, naldemedine — which would block both pharmacological opioid and dietary BCM-7 effects); prokinetic agents (metoclopramide, prucalopride, erythromycin — which would oppose BCM-7's local motility-slowing effects); and DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) used for type 2 diabetes — DPP-4 is the principal degrader of BCM-7, so DPP-4 inhibitor therapy could in theory prolong BCM-7 lifetime in the intestinal lumen, with unclear clinical significance. None of these interactions has been clinically characterized; they are mechanistic possibilities rather than documented events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions